Condition: Psoriatic Arthritis (PsA) · Obesity & Overweight · Sponsor: NHS Greater Glasgow and Clyde
This is a trial to find out how weight loss (achieved by the use of tirzepatide) or ixekizumab treatment affects the characteristics of skin, joint and fat tissues in patients with Psoriatic Arthritis, Psoriasis and obesity/overweight BMI \>=27. Participants will be allocated either Tirzepatide, Ixekizumab or both. Samples of joint tissue, fat and skin will be taken at the start of the study and week 12. Blood and urine samples will also be taken. The primary objective will be to assess the changes seen in the joint, fat and skin tissue samples 12 weeks after starting the medications (additional analysis will be done on the optional 36 week samples). Secondary objectives will be * To assess the changes seen in blood 4, 12, 36 and 52 weeks after starting the medication. * To compare the changes seen in tissue and blood between Ixekizumab and Tirzepatide/Weight loss. * To see how the changes seen in the tissue relate to weight loss.
This description comes directly from the study's public registry record.
Stefan Siebert, MBBCh, FRCP, PhD · +44 141 330 3375 · stefan.siebert@glasgow.ac.uk
Project Manager · +44 141 330 8408 · combat-psa@glasgow.ac.uk
Always discuss trial participation with your own doctor first.
| University Hospitals Birmingham NHS Foundation Trust | Birmingham, England, United Kingdom | Not Yet Recruiting |
| University Hospitals Coventry and Warwickshire NHS Trust | Coventry, England, United Kingdom | Not Yet Recruiting |
| The Newcastle Upon Tyne Hospitals NHS Foundation Trust | Newcastle upon Tyne, England, United Kingdom | Not Yet Recruiting |
| NHS Greater Glasgow and Clyde | Glasgow, Scotland, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07443956